{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:05Z","timestamp":1792794965672,"version":"4.5.0"},"reference-count":235,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids and benzodiazepines). We review these four classes of NPS, including their chemical structures, mechanism of action, modes of use, intended intoxicant effects, and their associated physical and mental health harms. The current challenges faced by laboratory testing for NPS are also explored, in the context of the diverse range of NPS currently available, rate of production and emergence of new substances, the different formulations, and methods of acquisition and distribution.<\/jats:p>","DOI":"10.1177\/2045125320967197","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:14:43Z","timestamp":1608250483000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":319,"title":["New psychoactive substances: a review and updates"],"prefix":"10.1177","volume":"10","author":[{"given":"Abu","family":"Shafi","sequence":"first","affiliation":[{"name":"East London Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Berry","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Sumnall","sequence":"additional","affiliation":[{"name":"Liverpool John Moores University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wood","sequence":"additional","affiliation":[{"name":"Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"Clinical Toxicology, Faculty of Life Sciences and Medicine, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-9407","authenticated-orcid":false,"given":"Derek K.","family":"Tracy","sequence":"additional","affiliation":[{"name":"Consultant Psychiatrist, Oxleas NHS Foundation Trust, London, UK"},{"name":"Department of Psychosis Studies, the Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, DeCrespigny Park, London, SE5 8AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02693-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32231-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2016.03.007"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.15406\/frcij.2019.07.00284"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2020.03.015"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02874.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.09.030"},{"key":"e_1_3_2_9_2","unstructured":"United Nations Office on Drugs and Crime. Global smart update 2016 https:\/\/www.unodc.org\/documents\/scientific\/Global-SMART-Update-2016-vol-16.pdf (accessed 4 April 2020)."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14168"},{"key":"e_1_3_2_11_2","first-page":"86","article-title":"British Journal of Clinical Pharmacology themed issue on new psychoactive substances: pharmacology influencing practice, policy and the law","author":"Corkery JM","year":"2019","unstructured":"Corkery JM, Schifano F, Martinotti G. British Journal of Clinical Pharmacology themed issue on new psychoactive substances: pharmacology influencing practice, policy and the law. Br J Clin Pharmacol 2019; 86.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_2_12_2","unstructured":"Legislation. Psychoactive substances act 2016 http:\/\/www.legislation.gov.uk\/ukpga\/2016\/2\/contents\/enacted (accessed 4 April 2020)."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14209"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13439"},{"key":"e_1_3_2_15_2","volume-title":"Review of the Psychoactive Substances Act 2016","author":"Home Office","year":"2018","unstructured":"Home Office. Review of the Psychoactive Substances Act 2016. London: Home Office, 2018."},{"key":"e_1_3_2_16_2","unstructured":"United Nations Office on Drugs and Crime. Current NPS threats March 2019 https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_Threats_Volume_I.pdf (accessed 4 April 2020)."},{"key":"e_1_3_2_17_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European drug report 2019: trends and developments http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11364\/20191724_TDAT19001ENN_PDF.pdf (2019). (accessed 4 April 2020)."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-015-0286-5"},{"key":"e_1_3_2_19_2","unstructured":"United Nations Office on Drugs and Crime. Understanding the synthetic drug market: the NPS factor https:\/\/www.unodc.org\/documents\/scientific\/Global_Smart_Update_2018_Vol.19.pdf (accessed 4 April 2020)."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102672"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2727"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030770"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1661425"},{"key":"e_1_3_2_24_2","unstructured":"Home Office. Drugs misuse: findings from the 2018\/19 crime survey for England and Wales. Statistical Bulletin: 21\/19 https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/832533\/drug-misuse-2019-hosb2119.pdf (accessed 19 September 2019)."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2016.10.003"},{"key":"e_1_3_2_26_2","volume-title":"Adult substance misuse statistics 2018 to 2019: report","author":"Public Health England","year":"2019","unstructured":"Public Health England. Adult substance misuse statistics 2018 to 2019: report. London: Public Health England, 2019."},{"key":"e_1_3_2_27_2","unstructured":"Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2018 registrations https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2018registrations (accessed 11 April 2020)."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6848"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00153"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-013-1163-9"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0193-z"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666141210224137"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2013.11.104"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.07.023"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2012.03.009"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78707-7_2"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00156"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78707-7_1"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227774"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-019-00485-y"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.11.024"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.020"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00151-x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2018.1448867"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjps.galenos.2018.40820"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2014.06.020"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00538-5"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.02.016"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.304"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-2967-2"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.04.004"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(97)00323-7"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1108\/DAT-07-2019-0028"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.32598\/ijmtfm.v10i1.26253"},{"key":"e_1_3_2_55_2","volume-title":"Drugs of abuse: a DEA resource guide","author":"Drug Enforcement Administration","year":"2017","unstructured":"Drug Enforcement Administration. Drugs of abuse: a DEA resource guide. Springfield, VA: Drug Enforcement Administration, US Department of Justice, 2017."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-018-0668-2"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.40"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00438"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-018-0417-x"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2016.07.038"},{"key":"e_1_3_2_61_2","first-page":"805","volume-title":"Movement disorders","author":"Okujava M","year":"2017","unstructured":"Okujava M, Todua F, Janelidze M, et al Pattern of MRI findings in ephedronic encephalopathy. In: Movement disorders. Vol. 32. Hoboken, NJ: Wiley, 2017, pp.805\u2013949."},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102703"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.008"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2019.0447"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091450920919456"},{"key":"e_1_3_2_66_2","volume-title":"The ADHD explosion: myths, medication, money, and today\u2019s push for performance","author":"Hinshaw SP","year":"2014","unstructured":"Hinshaw SP, Scheffler RM. The ADHD explosion: myths, medication, money, and today\u2019s push for performance. New York, NY: Oxford University Press, 2014."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20180719-02"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000682"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.02.001"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1110590"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.130"},{"key":"e_1_3_2_72_2","unstructured":"United Nations Office on Drugs and Crime. Current NPS threats. Volume II. January 2020 https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_Threats_Volume_II_Web.pdf (accessed 18 April 2020)."},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_143"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1177\/1178221817701739"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20341"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.563"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1307345"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.07.011"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.13138."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115574493"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.12.011"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004563218767462"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkz092"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6540a4"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2018.1517178"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1686725."},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2016.02.024"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.09.017"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.12.212"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0004"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-013-0213-6"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1418"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5b00112"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5b00107"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2491"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2583"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00429"},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.03535","article-title":"Structure-activity relationships for Cumyl-containing synthetic cannabinoids to induce hypothermic, cataleptic and analgesic effects in mice","volume":"34","author":"Baumann MH","year":"2020","unstructured":"Baumann MH, Garibay N, Partilla JS, et al Structure-activity relationships for Cumyl-containing synthetic cannabinoids to induce hypothermic, cataleptic and analgesic effects in mice. FASEB J 2020; 34(Suppl. 1): 1.","journal-title":"FASEB J"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1647344"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-020-00534-x"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.08.002"},{"key":"e_1_3_2_102_2","first-page":"618","article-title":"Increase in reported adverse health effects related to synthetic cannabinoid use\u2014United States, January\u2013May 2015","volume":"64","author":"Law R","year":"2015","unstructured":"Law R, Schier J, Martin C, et al Increase in reported adverse health effects related to synthetic cannabinoid use\u2014United States, January\u2013May 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 618\u2013619.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2012.03.007"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-016-0584-2"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2241"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.08.051"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2015.04.176"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-019-09522-z"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.5543\/tkda.2017.84425"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.29252\/beat-0703019"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.017"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119826592"},{"key":"e_1_3_2_113_2","article-title":"The relevance of sex in the association of synthetic cannabinoid use with psychosis and agitation in an inpatient population","volume":"80","author":"Nia AB","year":"2019","unstructured":"Nia AB, Mann CL, Spriggs S, et al The relevance of sex in the association of synthetic cannabinoid use with psychosis and agitation in an inpatient population. J Clin Psychiatry 2019; 80:18m12539.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.05.017"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05238-8"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a039743."},{"key":"e_1_3_2_117_2","first-page":"000116","article-title":"The new classes of synthetic illicit drugs can significantly harm the brain: a neuro imaging perspective with full review of MRI findings","volume":"2","author":"Creagh S","year":"2018","unstructured":"Creagh S, Warden D, Latif MA, et al The new classes of synthetic illicit drugs can significantly harm the brain: a neuro imaging perspective with full review of MRI findings. Clin Radiol Imaging J 2018; 2: 000116.","journal-title":"Clin Radiol Imaging J"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4546-4"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-016-0694-1"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-016-9650-x"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.827"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.4236\/ijcm.2020.112006"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxics8010008"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314527985"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2017.11.017"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14700-6"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.802795"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0314-y"},{"key":"e_1_3_2_129_2","first-page":"191","volume-title":"The American psychiatric publishing textbook of substance abuse treatment","author":"Weaver MF","year":"2008","unstructured":"Weaver MF, Schnoll SH. Hallucinogens and club drugs. In: Kleber H, Galanter M (eds) The American psychiatric publishing textbook of substance abuse treatment. Washington, DC: American Psychiatric Publishing, 2008, pp.191\u2013200."},{"key":"e_1_3_2_130_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/appi.books.9781615372812.lg11","volume-title":"Clinical manual of youth addictive disorders","author":"Whitmore CA","year":"2019","unstructured":"Whitmore CA, Hopfer C. Youth club, prescription, and over-the-counter drug use. In: Kaminer Y, Winters KC (eds) Clinical manual of youth addictive disorders. Washington, DC: The American Psychiatric Association Publishing, 2019, p.229."},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-23961-3_5"},{"key":"e_1_3_2_132_2","volume-title":"PIHKAL: phenethylamines I have known and loved","author":"Shulgin A","year":"1995","unstructured":"Shulgin A, Shulgin A. PIHKAL: phenethylamines I have known and loved. Berkeley, CA: Transform Press, 1995."},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.09.024"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666141210222409"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2613"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-018-1558-9"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01423"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.05.014"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4988-3"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2019.12.001"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2018.1482261"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00132"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00100"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-018-1882-9"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1054502"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw108"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1004179"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.885983"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.815"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.12367"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/29.5.394"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.82"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0295-x"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAF.0000000000000082"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00612"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2000.2.3\/jnewcomer"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1620"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157021"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-018-0421-1"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05412-y"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059334"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.10.020"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12313"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-35284-4_5"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2016.1207827"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.10.022"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13952"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071556"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw054"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku052"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.892605"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2012.683437"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2017.02.034"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx092"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2215"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2012-202251"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1199-9"},{"key":"e_1_3_2_178_2","unstructured":"EMCDDA Perspectives on Drugs. The misuse of benzodiazepines among high-risk opioid users in Europe http:\/\/www.emcdda.europa.eu\/topics\/pods\/benzodiazepines_en (2018). (accessed 25 April 2020)."},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2019.02.015"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119901096"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_154"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.scijus.2017.12.004"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2211"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133348"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b04000"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2017.08.005"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1510502"},{"key":"e_1_3_2_188_2","first-page":"217","article-title":"The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum","volume":"34","author":"Andersson M","year":"2017","unstructured":"Andersson M, Kjellgren A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nordisk Alkohol Nark 2017; 34: 217\u2013229.","journal-title":"Nordisk Alkohol Nark"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2391."},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2016.12.020"},{"key":"e_1_3_2_191_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bky039"},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2015.07.033"},{"key":"e_1_3_2_193_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-6806-6_8"},{"key":"e_1_3_2_194_2","volume-title":"Opiate, opioid, narcotic-what\u2019s the difference","author":"Labonville S.","year":"2017","unstructured":"Labonville S. Opiate, opioid, narcotic-what\u2019s the difference. Winnipeg, MB: The Patient Advocate Pharmacy, 2017."},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170223"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.11.033"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.05.018"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00654"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00586"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04317.x"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.016"},{"key":"e_1_3_2_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.08.016"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.08.028"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01210"},{"key":"e_1_3_2_205_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2018.1554187"},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2019.11.025"},{"key":"e_1_3_2_207_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2878"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1303141"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.983239"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.04.010"},{"key":"e_1_3_2_211_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bky099"},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.04.030"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-018-1969-3"},{"key":"e_1_3_2_214_2","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2016.1271034"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232038"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.281626"},{"key":"e_1_3_2_217_2","volume-title":"Club drug use among lesbian, gay, bisexual and trans (LGBT) people","author":"Abdulrahim D","year":"2016","unstructured":"Abdulrahim D, Whiteley C, Moncrieff M, et al Club drug use among lesbian, gay, bisexual and trans (LGBT) people. London: Novel Psychoactive Treatment UK Network (NEPTUNE), 2016."},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.10.011"},{"key":"e_1_3_2_219_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.007"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku133"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-015-9247-4"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2017.06.022"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61628-5"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1505"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2018.03.039"},{"key":"e_1_3_2_226_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forc.2019.100189"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forc.2018.03.003"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.04.012"},{"key":"e_1_3_2_229_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2018.05.015"},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1340-5"},{"key":"e_1_3_2_231_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Hospital emergency presentations and acute drug toxicity in Europe \u2014 update from the Euro-DEN Plus research group and the EMCDDA Lisbon https:\/\/www.emcdda.europa.eu\/publications\/rapid-communications\/2016\/hospital-emergencies_en (accessed August 2016)."},{"key":"e_1_3_2_232_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network EMCDDA Lisbon https:\/\/www.emcdda.europa.eu\/publications\/technical-reports\/drug-related-hospital-emergency-presentations-in-europe (accessed February 2020)."},{"key":"e_1_3_2_233_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.898771"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1088157"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcv208"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25071722"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2045125320967197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2045125320967197","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2045125320967197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:52:10Z","timestamp":1777593130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2045125320967197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":235,"alternative-id":["10.1177\/2045125320967197"],"URL":"https:\/\/doi.org\/10.1177\/2045125320967197","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2045125320967197"}}